Repaglinide

• Background:

  Repaglinide is a blocker of the ATP-sensitive potassium channel Kir6 with hypoglycemic activity.1 Clinically useful antidiabetic agent. It displays 30-fold selectivity for pancreatic Kir6.2/SUR1 over cardiac Kir6.1/SUR2B and Kir6/SUR2A channels.2 Repaglinide displayed neuroprotective effects in Huntington disease3, Parkinson’s disease4, and ALS5 via blockade of the DREAM-ATF6 interaction.

• Conjugation:

  Unconjugated

• Buffer:

  White solid

• Storage Conditions:

  -20°C